| 词条 | Menotropin |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 447568131 | IUPAC_name = | image = | tradename = Repronex | MedlinePlus = a601002 | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 61489-71-2 | ATC_prefix = G03 | ATC_suffix = GA02 | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 5Y9QQM372Q | chemical_formula = | molecular_weight = }}Menotropin (also called human menopausal gonadotropin or hMG) is a hormonally active medication for the treatment of fertility disturbances. Frequently the plural is used as the medication is a mixture of gonadotropins. Menotropins are extracted from the urine of postmenopausal women.[1] Description and usageUrine of postmenopausal women reflects the hypergonadotropic state of menopause -levels of follicle stimulating hormone (FSH) and luteinizing hormone (LH) are high - and contain a mixture of these gonadotropins.[2][3][4] Other protein substances may be present, including small amounts of human chorionic gonadotropin (hCG).[1] In 1949 Piero Donini found a relatively simple method to extract gonadotropins from urine of postmenopausal women.[4][4] Menotropins were successfully introduced into clinical use by Bruno Lunenfeld in 1961.[5] While earlier menotropin medications contained FSH and LH at a 1:1 ratio, the recognition that it is FSH that is critical for follicle stimulation has led to development of newer preparations that contain a much higher FSH/LH ratio, Fertinex being an example.[5] Menotropin preparations are designed for use in selected women where they stimulate the ovaries to mature follicles, thus making them more fertile. They are administered by typically daily injection, intramuscularly or subcutaneously, for about ten days under close supervision to adjust dose and duration of therapy. They can also be used in hypogonadal men to stimulate sperm production. Human urinary-derived menotropin preparations are exposed to the theoretical risk of infection from menopausal donors of urine. Nevertheless, the failure to irrefutably demonstrate infectivity following intracerebral inoculation with urine from transmissible spongiform encephalopathy(TSE)-infected hosts suggests that the risk associated with products derived from urine is merely theoretical.[6] Recombinant gonadotropins have to a large degree replaced hMG in fertility treatments. The recombinant process allows for the production of pure FSH or LH not "contaminated" by other proteins that may be present after urinary extraction. While some head-on studies seem not to suggest that "pure FSH" gives better results than hMG.,[7] others claim that recombinant FSH is more efficient and reduces costs.[8] A Cochrane Collaboration analysis did not reveal major differences in clinical outcomes when comparing urinary versus recombinant FSH.[9]The Practice Committee of the American Society for Reproductive Medicine reported:[10] “Compared with earlier crude animal extracts, modern highly purified urinary and recombinant gonadotropin products have clearly superior quality, specific activity, and performance. There are no confirmed differences in safety, purity, or clinical efficacy among the various available urinary or recombinant gonadotropin products.” List of hMG preparationsA number of drug companies have and had marketed hMG preparations that include:[11]
Highly purified urinary FSH and LH in 1:1 ratio
highly purified urinary FSH and LH in 1:1 ratio
highly purified urinary FSH
Pergonal was the major hMG prior to the arrival of recombinant gonadotropins containing 75 IU FSH and 75 IU LH.
See also
References1. ^1 {{Cite journal| doi = 10.1016/S1472-6483(10)62071-8| last1 = Van De Weijer | first1 = B. H.| last2 = Mulders | first2 = J. W.| last3 = Bos | first3 = E. S.| last4 = Verhaert | first4 = P. D.| last5 = Van Den Hooven | first5 = H. W.| title = Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities| journal = Reproductive Biomedicine Online| volume = 7| issue = 5| pages = 547–557| year = 2003| pmid = 14680547}} {{GnRH and gonadotropins}}{{Assisted reproductive technology}}{{GnRH and gonadotropin receptor modulators}}2. ^{{MeshName|Menotropins}} 3. ^TheFreeDictionary > Menotropin Citing: Dorland's Medical Dictionary for Health Consumers. 2007 4. ^{{cite web| url=http://www.lifesciencesfoundation.org/printer_events-item-818.html| author=Unknown| title=Serono goes recombinant| publisher=Serono Laboratories, 2011| accessdate=2013-11-24| deadurl=yes| archiveurl=https://web.archive.org/web/20131202225817/http://www.lifesciencesfoundation.org/printer_events-item-818.html| archivedate=2013-12-02| df=}} 5. ^1 2 3 {{cite journal |url=http://humupd.oxfordjournals.org/content/10/6/453.full|author=Lunenfeld B |title=Historical perspectives in gonadotropin therapy|journal=Human Reproduction Update |year=2004 |volume=10 |issue=6 |pages=453–467 |doi=10.1093/humupd/dmh044|pmid=15388674 |accessdate=2013-11-25}} 6. ^{{cite journal |vauthors=Reichl H, Balen A, Jansen CA |title=Prion transmission in blood and urine: what are the implications for recombinant and urinary-derived gonadotrophins? |journal=Hum. Reprod. |volume=17 |issue=10 |pages=2501–8 |date=October 2002 |pmid=12351519|doi=10.1093/humrep/17.10.2501}} 7. ^{{Cite journal | last1 = Bagratee | first1 = J. S. | last2 = Lockwood | first2 = G. | last3 = López Bernal | first3 = A. | last4 = Barlow | first4 = D. H. | last5 = Ledger | first5 = W. L. | title = Comparison of highly purified FSH (metrodin-high purity) with pergonal for IVF superovulation | journal = Journal of Assisted Reproduction and Genetics | volume = 15 | issue = 2 | pages = 65–69 | year = 1998 | pmid = 9513843 | pmc = 3455420 | doi = 10.1007/BF02766827}} 8. ^{{Cite journal | doi = 10.1093/humrep/16.12.2563 | last1 = Daya | first1 = S. | last2 = Ledger | first2 = W. | last3 = Auray | first3 = J. P. | last4 = Duru | first4 = G. | last5 = Silverberg | first5 = K. | last6 = Wikland | first6 = M. | last7 = Bouzayen | first7 = R. | last8 = Howles | first8 = C. M. | last9 = Beresniak | first9 = A. | title = Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK | journal = Human Reproduction (Oxford, England) | volume = 16 | issue = 12 | pages = 2563–2569 | year = 2001 | pmid = 11726575}} 9. ^{{Cite journal | last1 = Van Wely | first1 = M. | last2 = Kwan | first2 = I. | last3 = Burt | first3 = A. L. | last4 = Thomas | first4 = J. | last5 = Vail | first5 = A. | last6 = Van Der Veen | first6 = F. | last7 = Al-Inany | first7 = H. G. | editor1-last = Van Wely | editor1-first = Madelon | title = Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles | doi = 10.1002/14651858.CD005354.pub2 | journal = The Cochrane Library| issue = 2 | pages = CD005354 | year = 2011 | pmid = 21328276 | pmc = }} 10. ^{{cite journal |title=Gonadotropin preparations: past, present, and future perspectives |journal=Fertil. Steril. |volume=90 |issue=5 Suppl |pages=S13–20 |date=November 2008 |pmid=19007609 |doi=10.1016/j.fertnstert.2008.08.031 |author1= Practice Committee Of American Society For Reproductive Medicine |first1= Birmingham}} 11. ^{{cite book | last = Fuller | first = Matthew A. |author2=Martha Sajatovic | title = Drug Information Handbook for Psychiatry | edition = 4 | publisher = Lexi-Comp, Inc. | year = 2003 | isbn = 978-1-59195-064-6 | page = 711}} 3 : Drugs acting on the genito-urinary system|Gonadotropin-releasing hormone and gonadotropins|Human female endocrine system |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。